



## Coronary In-Stent Restenosis – Current Perspectives

Guest Editors:

### Dr. Leoš Pleva

1. Department of Cardiovascular Diseases, Internal and Cardiology Clinic, University Hospital Ostrava, 70833 Ostrava, Czech Republic
2. Medical Faculty, University of Ostrava, 70833 Ostrava, Czech Republic

### Dr. Ota Hlinomaz

1. International Clinical Research Center, St. Anne's University Hospital, Pekarska 53, 656 91 Brno, Czech Republic
2. Center for Interventional Neuroradiology and Endovascular Therapy, Bratislava, Slovak Republic
3. Univmed s.r.o., Brno, Czech Republic

Deadline for manuscript submissions:

**closed (30 June 2024)**

### Message from the Guest Editors

Percutaneous coronary intervention (PCI), which allows the removal of coronary obstruction and restoration of supply to the affected myocardium, has brought major improvements in the treatment of coronary artery disease. Coronary stents allowed management of early periprocedural complications and led to a lower occurrence of restenosis following the plane balloon angioplasty due to the restricted elastic recoil and constrictive remodelling. The development of neointimal hyperplasia is, however, a novel complication associated with stent implantation possibly causing recurrence of the narrowing of the vessel lumen, the so-called in-stent restenosis (ISR). Although the use of drug-eluting stents (DES) contributed to their lower occurrence, in-stent restenosis remains one of the essential limitations of coronary interventions. In addition, the restenosis in drug-eluting stent (DES-ISR), is a complex process involving not only the intrinsic reaction of the vessel wall to the metallic stent platform, but also the biocompatibility of the polymer coating or insufficient effect of the antiproliferative drug, making the treatment of these remaining DES-ISR even more challenging.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Thomas Brand

National Heart & Lung Institute,  
Imperial College London, South  
Kensington Campus, London  
SW7 2AZ, UK

## Message from the Editor-in-Chief

The primary goal of the *Journal of Cardiovascular Development and Disease (JCDD)*, ISSN 2308-3425) is to provide cardiovascular scientists a platform to publish their work in a quick and efficient way. Topics can range from studies designed to decipher the events underlying early heart development to studies focusing on the origins of congenital and acquired heart disease. Papers submitted to *JCDD* undergo a fast, yet thorough, peer-review process. In this process, we will apply strict ethical policies and standards. *JCDD* guarantees fast dissemination of results to a large scientific audience.

## Author Benefits

**Open Access:**— free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

**High Visibility:** indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [Embase](#), [CAPlus / SciFinder](#), and other databases.

**Journal Rank:** JCR - Q2 (Cardiac and Cardiovascular Systems) / [CiteScore - Q2](#) (General Pharmacology, Toxicology and Pharmaceutics)

## Contact Us

---

*Journal of Cardiovascular  
Development and Disease* Editorial  
Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/jcdd](http://mdpi.com/journal/jcdd)  
[jcdd@mdpi.com](mailto:jcdd@mdpi.com)  
[X@JCDD\\_MDPI](https://twitter.com/X@JCDD_MDPI)